|
🐜
|
Phase I and Pharmacokinetic Studies of CYT-6091, a Novel PEGylated Colloidal Gold-rhTNF Nanomedicine
9 auth.
S. Libutti,
G. Paciotti,
A. Byrnes,
H. Alexander,
W. Gannon,
M. Walker,
...
G. Seidel,
N. Yuldasheva,
L. Tamarkin
|
9 |
2010 |
9
🐜
|
|
🐜
|
Results of a completed phase I clinical trial of CYT-6091: A pegylated colloidal gold-TNF nanomedicine.
10 auth.
S. Libutti,
G. Paciotti,
L. Myer,
R. Haynes,
W. Gannon,
M. Walker,
...
G. Seidel,
A. Byrnes,
N. Yuldasheva,
L. Tamarkin
|
5 |
2009 |
5
🐜
|
|
🐜
|
Preliminary results of a phase I clinical trial of CYT-6091: A pegylated colloidal gold-TNF nanomedicine
10 auth.
S. Libutti,
G. Paciotti,
L. Myer,
R. Haynes,
W. Gannon,
Michelle A. Eugeni,
...
G. Seidel,
Y. Shutack,
N. Yuldasheva,
L. Tamarkin
|
4 |
2007 |
4
🐜
|
|
🐬
|
PRTX‐100 and methotrexate in patients with active rheumatoid arthritis: A Phase Ib randomized, double‐blind, placebo‐controlled, dose‐escalation study
E. Bernton,
W. Gannon,
W. Kramer,
Eduard Kranz
|
3 |
2014 |
3
🐬
|
|
🐜
|
Phase 1 open-label trial to evaluate the safety and immunogenicity of PAN-301-1, a novel nanoparticle therapeutic vaccine, in patients with biochemically relapsed prostate cancer.
8 auth.
L. Nordquist,
N. Shore,
J. Elist,
J. Oliver,
W. Gannon,
A. Shahlaee,
...
S. Fuller,
H. Ghanbari
|
2 |
2018 |
2
🐜
|
|
🐜
|
Final results from a phase i clinical trial evaluating the safety, immunogenicity, and anti-tumor activity of SNS-301 in men with biochemically relapsed prostate cancer.
8 auth.
L. Nordquist,
H. Ghanbari,
J. Elist,
J. Oliver,
W. Gannon,
A. Shahlaee,
...
S. Fuller,
N. Shore
|
1 |
2018 |
1
🐜
|
|
🐢
|
Oral Valacyclovir Treatment of Herpes Zoster Ophthalmicus-Induced Optic Neuritis
C. Hunt,
Hannah M Gregory,
W. Gannon
|
0 |
2021 |
0
🐢
|
